Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Vistusertib (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Liver cancer; Neuroendocrine carcinoma; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Therapeutic Use
- Acronyms RICTOR_SC
- 17 May 2019 Planned End Date changed from 1 Dec 2019 to 31 Jul 2018.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2018.
- 17 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.